These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37212792)

  • 21. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
    Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
    Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Short NJ; Macaron W; Konopleva M; Ravandi F; Jain N; Issa GC; Kadia T; Sasaki K; Kebriaei P; Yilmaz M; Thompson PA; Takahashi K; Abbas HA; Wierda WG; Garris R; Kantarjian HM; Jabbour E
    Am J Hematol; 2022 Jun; 97(6):E201-E204. PubMed ID: 35266566
    [No Abstract]   [Full Text] [Related]  

  • 24. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
    Shimony S; Luskin MR
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
    Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report.
    Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.
    Russell-Smith A; Murphy L; Nguyen A; Blauer-Peterson C; Terpenning M; Cao F; Li S; Bancroft T; Webb N; Dorman S; Shah R
    J Comp Eff Res; 2024 Feb; 13(2):e230142. PubMed ID: 38099517
    [No Abstract]   [Full Text] [Related]  

  • 29. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Vandendries E; Pagé V; Cappelleri JC; Stelljes M
    Adv Ther; 2020 Feb; 37(2):958-962. PubMed ID: 31838711
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
    Okura M; Ida N; Yamauchi T
    Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
    Fuster JL; Molinos-Quintana A; Fuentes C; Fernández JM; Velasco P; Pascual T; Rives S; Dapena JL; Sisinni L; López-Godino O; Palomo P; Villa-Alcázar M; Bautista F; González-Vicent M; López-Duarte M; García-Morín M; Ramos-Elbal E; Ramírez M;
    Br J Haematol; 2020 Sep; 190(5):764-771. PubMed ID: 32314348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
    Aldoss I; Afkhami M; Yang D; Gu Z; Mokhtari S; Shahani S; Pourhassan H; Agrawal V; Koller P; Arslan S; Tomasian V; Al Malki MM; Artz A; Salhotra A; Ali H; Aribi A; Sandhu KS; Ball B; Otoukesh S; Amanam I; Becker PS; Stewart FM; Curtin P; Smith E; Telatar M; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
    Am J Hematol; 2023 Jun; 98(6):848-856. PubMed ID: 36880203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w.
    Song J; Gao W; Xie J; Tiwana S
    Adv Ther; 2020 Feb; 37(2):955-957. PubMed ID: 31838710
    [No Abstract]   [Full Text] [Related]  

  • 37. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
    Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
    Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
    Dhakal P; Kaur J; Gundabolu K; Bhatt VR
    Leuk Lymphoma; 2020 Jan; 61(1):7-17. PubMed ID: 31317803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.